Minh-Minh Ho1, Ayla Manughian-Peter1, Weston R Spivia1, Adam Taylor1, Deborah A Fraser2. 1. Department of Biological Sciences, California State University Long Beach, Long Beach, CA, USA. 2. Department of Biological Sciences, California State University Long Beach, Long Beach, CA, USA. Electronic address: Deborah.fraser@csulb.edu.
Abstract
BACKGROUND AND AIMS: This study investigated the effect of innate immune protein C1q on macrophage programmed responses during the ingestion of atherogenic lipoproteins. C1q plays a dual role in atherosclerosis where activation of complement by C1q is known to drive inflammation and promote disease progression. However, C1q is atheroprotective in early disease using mouse models. Our previous studies have highlighted a non-complement associated role for C1q in polarizing macrophages towards an M2-like anti-inflammatory phenotype during ingestion of targets such as atherogenic lipoproteins. This study aims to investigate the molecular mechanisms involved. METHODS: We investigated the molecular signaling mechanisms involved in macrophage polarization using an unbiased examination of gene expression profiles in human monocyte derived macrophages ingesting oxidized or acetylated low density lipoproteins in the presence or absence of C1q. RESULTS: Expression of genes involved in Janus kinase and signal transducer and activator of transcription (JAK-STAT) signaling, peroxisome proliferator activating receptor (PPAR) signaling and toll-like receptor (TLR) signaling were modulated by C1q in this screen. C1q was also shown to significantly suppress JAK-STAT pathway activation (a maximum 55% ± 13% reduction, p = 0.044) and increase transcriptional activation of PPARs (a maximum 229% ± 54% increase, p = 0.0002), consistent with an M2-like polarized response. These pathways were regulated in macrophages by C1q bound to different types of modified atherogenic lipoprotein and led to a reduction in the release of pro-inflammatory cytokine IL-6. CONCLUSIONS: This study identifies potential molecular mechanisms for the beneficial role C1q plays in early atherosclerosis.
BACKGROUND AND AIMS: This study investigated the effect of innate immune protein C1q on macrophage programmed responses during the ingestion of atherogenic lipoproteins. C1q plays a dual role in atherosclerosis where activation of complement by C1q is known to drive inflammation and promote disease progression. However, C1q is atheroprotective in early disease using mouse models. Our previous studies have highlighted a non-complement associated role for C1q in polarizing macrophages towards an M2-like anti-inflammatory phenotype during ingestion of targets such as atherogenic lipoproteins. This study aims to investigate the molecular mechanisms involved. METHODS: We investigated the molecular signaling mechanisms involved in macrophage polarization using an unbiased examination of gene expression profiles in human monocyte derived macrophages ingesting oxidized or acetylated low density lipoproteins in the presence or absence of C1q. RESULTS: Expression of genes involved in Janus kinase and signal transducer and activator of transcription (JAK-STAT) signaling, peroxisome proliferator activating receptor (PPAR) signaling and toll-like receptor (TLR) signaling were modulated by C1q in this screen. C1q was also shown to significantly suppress JAK-STAT pathway activation (a maximum 55% ± 13% reduction, p = 0.044) and increase transcriptional activation of PPARs (a maximum 229% ± 54% increase, p = 0.0002), consistent with an M2-like polarized response. These pathways were regulated in macrophages by C1q bound to different types of modified atherogenic lipoprotein and led to a reduction in the release of pro-inflammatory cytokine IL-6. CONCLUSIONS: This study identifies potential molecular mechanisms for the beneficial role C1q plays in early atherosclerosis.
Authors: Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker Journal: Genome Res Date: 2003-11 Impact factor: 9.043
Authors: Krzysztof Sikorski; Anna Czerwoniec; Janusz M Bujnicki; Joanna Wesoly; Hans A R Bluyssen Journal: Cytokine Growth Factor Rev Date: 2011-07-12 Impact factor: 7.638
Authors: Pieter Goossens; Marion J J Gijbels; Alma Zernecke; Wouter Eijgelaar; Monique N Vergouwe; Ingeborg van der Made; Joris Vanderlocht; Linda Beckers; Wim A Buurman; Mat J A P Daemen; Ulrich Kalinke; Christian Weber; Esther Lutgens; Menno P J de Winther Journal: Cell Metab Date: 2010-08-04 Impact factor: 27.287
Authors: A Chawla; W A Boisvert; C H Lee; B A Laffitte; Y Barak; S B Joseph; D Liao; L Nagy; P A Edwards; L K Curtiss; R M Evans; P Tontonoz Journal: Mol Cell Date: 2001-01 Impact factor: 17.970
Authors: John S Welch; Mercedes Ricote; Taro E Akiyama; Frank J Gonzalez; Christopher K Glass Journal: Proc Natl Acad Sci U S A Date: 2003-05-09 Impact factor: 11.205
Authors: Andrea J De Micheli; Emily J Laurilliard; Charles L Heinke; Hiranmayi Ravichandran; Paula Fraczek; Sharon Soueid-Baumgarten; Iwijn De Vlaminck; Olivier Elemento; Benjamin D Cosgrove Journal: Cell Rep Date: 2020-03-10 Impact factor: 9.423
Authors: Andreas Patsalos; Laszlo Halasz; Miguel A Medina-Serpas; Wilhelm K Berger; Bence Daniel; Petros Tzerpos; Máté Kiss; Gergely Nagy; Cornelius Fischer; Zoltan Simandi; Tamas Varga; Laszlo Nagy Journal: J Exp Med Date: 2021-11-30 Impact factor: 14.307